A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With SLE
A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With SLE
M2951 is an investigational drug under evaluation for treatment of autoimmune and inflammatory disorders. The purpose of the study was to assess the Safety and Efficacy of M2951 in participants with Systemic Lupus Erythematosus (SLE).
Inclusion Criteria:
Exclusion Criteria:
Seattle, Washington, United States
Ciudad Autonoma Buenos Aires, Argentina
Ciudad Autonoma Buenos Aires, Argentina
Ciudad Autonoma Buenos Aires, Argentina
Ciudad Autonoma Buenos Aires, Argentina
Ciudad Autonoma Buenos Aires, Argentina
Naples, Italy
Toon-shi, Ehime, Japan
Kitakyushu-shi, Fukuoka, Japan
Kitakyushu-shi, Fukuoka, Japan
Asahikawa-shi, Hokkaido, Japan
Kita-gun, Kagawa-ken, Japan
Shimotsuga-gun, Tochigi, Japan
Fuchu-shi, Tokyo-To, Japan
Itabashi-ku, Tokyo-To, Japan
Shinjuku-ku, Tokyo-To, Japan
Yonago-shi, Tottori, Japan
Bukit Jalil, Selangor, Malaysia
Solferino-Phoenix, Mauritius
Angeles City, Pampanga, Philippines
Dasmariñas City, Cavite, Philippines
Elblag, Poland
Krasnoyarsk, Russia